MONTREAL and CHARLOTTE, N.C. , Nov. 21, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28, 2023 , at 10:30 a.m.

New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST ™ , the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific

E tripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate  (p

Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm , MD, and Sean Pokorney , MD Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C. , Nov. 7, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc.

Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT Comprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates new calcium channel blocker, etripamil ,  is twice as

MONTREAL and CHARLOTTE, N.C. , Oct. 6, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 122,000 options (the "Options") to purchase the Company's common shares,

MONTREAL and CHARLOTTE, N.C. , Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study will be presented at the American Heart Association (AHA) Scientific Sessions 2023.

MONTREAL and CHARLOTTE, N.C. , Sept. 5, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a

NDA submission for etripamil in patients with PSVT expected in October 2023 Data featured during oral session at Heart Rhythm 2023 Annual Meeting support the potential of etripamil in patients with AFib-RVR Enrollment complete in Phase 2 ReVeRA study of etripamil in patients with AFib-RVR; topline

-      Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p